Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment

Antiviral Therapy

Volumn 17, Issue 8, 2012, Pages 1615-1619

  De Pablo, Carmen ^a   Orden, Samuel ^a   Calatayud, Sara ^a   Martí Cabrera, Miguel ^a   Esplugues, Juan V ^a,b   Álvarez, Ángeles ^a,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALPHA4 INTEGRIN; CD11B ANTIGEN; CD18 ANTIGEN; CELL ADHESION MOLECULE; EMTRICITABINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LAMIVUDINE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; TENOFOVIR; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LEUKOCYTE; MONOCYTE; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

ADENINE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL ADHESION; CELL ADHESION MOLECULES; CELL COMMUNICATION; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; ENDOTHELIAL CELLS; HIV INFECTIONS; HUMANS; LAMIVUDINE; LEUKOCYTES; ORGANOPHOSPHONATES;

EID: 84871870894     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2357     Document Type: Article

References (22)

1. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.
2. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929-940.
3. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-1426.
4. The SMART/INSIGHT and the D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
5. Behrens GM, Reiss P. Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010; 23:9-14.
6. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84:2068-2101. (Pubitemid 24296363)
7. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115:3378-3384. (Pubitemid 43121822)
8. De Pablo C, Orden S, Apostolova N, Blanquer A, Esplugues JV, Alvarez A. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. AIDS 2010; 24:1259-1266.
9. Goetz DJ, Greif DM, Shen J, Luscinskas FW. Cell-cell adhesive interactions in an in vitro flow chamber. Methods Mol Biol 1999; 96:137-145.
10. Luscinskas FW, Kansas GS, Ding H, et al. Monocyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, beta 1-integrins, and beta 2-integrins. J Cell Biol 1994; 125:1417-1427.
11. Gee DJ, Wright LK, Zimmermann J, Cole K, Soule K, Ubowski M. Dimethylsulfoxide exposure modulates HL-60 cell rolling interactions. Biosci Rep 2012; 32:375-382.
12. Wang X, Chai H, Lin PH, Yao Q, Chen C. Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 2009; 174:771-781.
13. Parks DA, Jennings HC, Taylor CW, Acosta EP. Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. AIDS 2007; 21:1373-1375. (Pubitemid 46883497)
14. Victor VM, Rocha M, Banuls C, et al. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab 2011; 96:3115-3122.
15. Gallego MJ, Zoja C, Morigi M, et al. Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. Am J Kidney Dis 1996; 28:23-31. (Pubitemid 26231462)
16. Hirahashi J, Hishikawa K, Kaname S, et al. Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. Circulation 2009; 120:1255-1265.
17. Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS 2011; 25:2243-2248.
18. Rasmussen TA, Tolstrup M, Melchjorsen J, et al. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis 2011; 11:267.
19. Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011; 11:40.
20. Sinn K, Richardson R, Carr A. Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk. AIDS 2010; 24:2403-2405.
21. Francisci D, Falcinelli E, Belfiori B, et al. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction. AIDS Patient Care STDS 2011; 25:567-569.
22. Melchjorsen J, Risor MW, Sogaard OS, et al. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr 2011; 57:265-275.